Abstract
incubation, the non-migrated cells were removed from the top of the filter using cotton swabs, then cells that had migrated to the bottom were fixed in crystal violet for 2 h, and counted.
Tube formation assay 48-well plated was coated with 200 μl Matrigel (BD Biosciences, USA) and incubated at 37 ℃ for 30 min to form gels. 2×10
4 cells per well cells were seeded and incubated with 2% FBS ECM for 4 h. The length of the tubes and the branches number were measured using Image J software.
Statistical analysis
All measurements were presented as the averages of three independent replicates. Differences of the protein expression among the three groups were tested by one-way analysis of variance (ANOVA). Least Significant Difference (LSD) test was used for post hoc test in ANOVA. All these analyses were performed with SPSS 18.0 software (SPSS Inc, Chicago, IL, USA). All tests were two-sided, p-value < 0.05 was considered as statistically significant.
Results

TXL decreased apoptosis of CMECs in a concentration-dependent manner
To investigate the protective role of TXL on CMECs under hypoxia/reoxygenation (H/R) conditions, cells with different concentrations of TXL were detected by flow cytometry (Fig.  1) . The apoptotic rate of CMECs had a significant increase with H/R injury compared with the control group (28.73 ± 0.64% vs. 5 .81 ± 0.61%, p < 0.05). TXL dose-dependently attenuated H/R-induced apoptosis, and the best protective effect was noted with 800 μg/mL TXL. To detect the proteins of CMECs after H/R and how it is modulated by TXL, we used tandem mass tag labeling proteomics to reveal the change of proteins. CMECs in normal conditions (Group N), CMECs in H/R conditions (Group HR), and CMECs treated with TXL in H/R conditions (Group HR+TXL) were detected respectively, and TXL at 800 μg/mL was used because of its optimal effect of anti-apoptosis. There were three repetitions in each group.
Clustering analysis. Clustering analysis of nine samples was done according to all detected proteins and the differential proteins, respectively. The results of three independent replicates of each group were showed in Fig. 2 . There were substantial differences in the expression of proteins among three groups.
Analysis of differential proteins. Among the 4537 detected proteins, 50 differentially expressed proteins were identified totally in three groups by TMT-labeled proteomics using Fig. 2 . Clustering analysis of the 50 differentially expressed proteins in nine samples. H/R: Hypoxia/Reoxygenation. Protein names corresponded to gene symbols: HMOX1, heme oxygenase 1; RGCC, regulator of cell cycle RGCC; SOX17, transcription factor SOX-17; PSIP1, PC4 and SFRS1-interacting protein isoform 2; GLS, glutaminase kidney isoform, mitochondrial isoform 1; CYP1A1, cytochrome P450 1A1; CDKN1B, cyclin-dependent kinase inhibitor 1B; TBC1D10B, TBC1 domain family member 10B; SQSTM1, sequestosome-1 isoform 1; ACSM2B, acyl-coenzyme A synthetase ACSM2B, mitochondrial; SDF4, 45 kDa calcium-binding protein isoform 2 precursor; CTSL, cathepsin L1 isoform 2; ANGPT2, angiopoietin-2 isoform c precursor; UBL5, ubiquitin-like protein 5; LOC101930123, eukaryotic elongation factor 2 kinase; COA5, cytochrome c oxidase assembly factor 5; THBS1, thrombospondin-1 precursor; CTGF, connective tissue growth factor precursor; POSTN2_precursor, periostin isoform 2 precursor; POSTN3_precursor, periostin isoform 3 precursor; RPS27L, 40S ribosomal protein S27-like; ITIH2, inter-alpha-trypsin inhibitor heavy chain H2 precursor; PPP1R2, protein phosphatase inhibitor 2; BST1, ADP-ribosyl cyclase 2 precursor; SHPK, sedoheptulokinase; GOLM1, Golgi membrane protein 1; UBE2G1, ubiquitin-conjugating enzyme E2 G1; ZFYVE1, zinc finger FYVE domain-containing protein 1 isoform 2; F2, prothrombin preproprotein; MAP1LC3B, microtubule-associated proteins 1A/1B light chain 3B; SERPINF2, alpha-2-antiplasmin isoform b precursor; FBLN1, fibulin-1 isoform D precursor; ISYNA1, inositol-3-phosphate synthase 1 isoform 4; PPIL4, peptidyl-prolyl cis-trans isomerase-like 4; HBA1, hemoglobin subunit alpha; APOA1, apolipoprotein A-I preproprotein; AMOT, angiomotin isoform 2; HBB, hemoglobin subunit beta; GC, vitamin D-binding protein isoform 1 precursor; ALB, serum albumin preproprotein; ZNF614, zinc finger protein 614; A2M, alpha-2-macroglobulin precursor; HEART1, HEAT repeat-containing protein 1; HAUS4, HAUS augmin-like complex subunit 4 isoform 2; AFP, alpha-fetoprotein precursor; PATJ, crumbs cell polarity complex component; UNC80, protein unc-80 homolog isoform 2; CFAP100, cilia and flagella associated protein 100. AHSG, alpha-2-HS-glycoprotein preproprotein; LTF, lactotransferrin isoform 2. ANOVA analysis (p < 0.05), every identified protein had 1.5 fold change at least. These values are expressed on a log scale. Compared with group N, 30 proteins were significantly down-regulated in group HR, among which lactoferrin (lactotransferrin isoform 2, LTF) has the largest decline (Fig. 3A) . Compared with group HR, TXL 800 μg/mL treatment up-regulated 6 proteins and down-regulated 5 proteins. HMOX1 and precursor of connective tissue growth factor (connective tissue growth factor, CTGF) had the largest up-regulation and down-regulation, respectively (Fig. 3B ). Top 10 representative differential proteins between different groups had been showed in Suppl. Table 1 (for all online suppl. material, see www.karger.com/ doi/10.1159/000470806).
There were 6 proteins obviously down-regulated in H/R injury and up-regulated to normal level through TXL treatment (Fig. 4A ). There were 9 proteins with no obvious change in H/R injury but up-regulated significantly than normal through TXL treatment. Among them, the level of 5 proteins in group HR+TXL was much higher than group HR and the level of 4 proteins showed no statistical significance (Fig. 4B ). There were 7 proteins with no obvious change in H/R injury but down-regulated significantly than normal through TXL treatment. Among them, the level of 2 proteins in group HR+TXL was much lower than group HR and 5 proteins level showed no statistical significance (Fig. 4C) .
Gene Ontology (GO) analysis. Functions of differentially expressed proteins among three groups were detected by GO analysis (see supplementary material, Suppl. Table 2 ). The functions of differential proteins in the H/R included negative regulation of hydrolase activity, humoral immune response, regulation of inflammatory response, regulation of response to external stimulus, platelet degranulation, acute inflammatory response, and regulation of biomineral tissue development. TXL treatment could significantly change the expression of many proteins. These proteins played an important role in the areas mainly including response to oxygen levels, response to hypoxia, negative regulation of cellular component movement, regulation of response to stimulus, cell motility, cell migration, collagen metabolic process, regulation of developmental process, and cellular component movement.
Functions and pathways of differential proteins. We also analyzed functions and pathways of differentially expressed proteins according to enrichment p-value (Fig. 5) . These functions and pathways included cellular response to stimulus, cell migration, regulation of cellular component movement, regulation of lipoprotein, actin filament bundle, and enzyme activator activity (Fig. 5) . Some proteins had more than one function such as HMOX1, angiopoietin-2 isoform c precursor (ANGPT2), connective tissue growth factor precursor (CTGF), apolipoprotein A-I preproprotein (APOA1).
Identification and functional analysis of HMOX and the regulation of TXL. Western analysis was performed in order to identify the expression of HMOX (Fig. 6A, B) . The expression of HMOX had no significant difference between group H/R and group N, while it was significantly unregulated (p < 0.05) in TXL group compared with other groups. Furthermore, the addition of HMOX inhibitor had no change of the protein expression. To determine the function of HMOX during H/R in CMECs, further analysis were performed. Flow cytometry results indicated that, compared with the control group, H/SD significantly increased the percentage of apoptotic cells (6.60 ± 2.05% vs. 23.23 ± 2.78% in control group, p < 0.05). Conversely, TXL treatment led to a decrease (14.53 ± 1.53%) in apoptotic cells induced by H/SD and the anti-apoptotic effect of TXL was largely reduced by HMOX inhibitor TinPPIX (32.90 ± 2.33%) (Fig. 6C, D) . As shown in Fig. 6E , CCK8 assay showed that inhibition of HMOX led to remarkably reduction of cell proliferation than TXL treatment alone both at 24 h (0.13 ± 0.02 vs. 0.44 ± 0.40 in TXL group, p < 0.05) and 48 h (0.34 ± 0.07 vs. 0.62 ± 0.02 in TXL group, p < 0.05) after H/R. Moreover, similar trend was observed in the cell migration assay and tube formation assay. TXL treatment significantly promoted the cell migration and angiogenesis than cells exposed to H/R condition. When cells were cultured with TinPPIX and TXL, the number of migrated cells, the tube length, and the branches number were significantly reduced compared with TXL group (Fig. 6F, G, H, I ). Identification and functional analysis of ANGPT2 and the regulation of TXL. The expression of ANGPT2 was detected by western blot and no significant difference was observed between group H/R and group N, while it was significantly down-regulated (p < 0.05) in TXL group compared with H/R group. Moreover, the addition of ANGPT2 plasmid led to overexpression of ANGPT2 (Fig. 7A, B) . As shown in Fig. 7C , D, cell apoptosis was ANGPT2 overexpression. Also, the pro-migration and pro-angiogenesis effects of TXL were significantly reduced when cells were cultured with both ANGPT2 plasmid and TXL (Fig. 7F,  G, H, I ).
Discussion
Endothelial dysfunction is considered as the initiating process and pathological basis of myocardial no-reflow and reperfusion injury [16] . TXL has been proved to effectively improve the cardiac microcirculation in previous studies [17, 18] . However, there is no explicit mechanism responsible for IR and the regulation by TXL. In this study, we utilized an acute in vitro CMEC ischemia/reperfusion injury model (2 h/2 h) and TMT-labeled proteomic analysis to detect the proteins in CMECs during I/R and its modulation by TXL. To the best of our knowledge, this is the first study to 1) systematically investigate the change of proteins in endothelial cells during I/R and to 2) explore the multiple mechanisms of the regulation at the whole cell level by firstly using proteomic analysis. Also, we find that TXL treatment can affect the level of proteins in CMECs.
We identified 50 differentially expressed proteins using TMT-labeled proteomics, which permits fast quantitative profiling of a large number of proteins from complex biological samples. We found that H/R could significantly alter the levels of 32 proteins. These proteins had different functions and are involved in a variety of processes during I/R. Alpha-2-macroglobulin precursor (A2M), APOA1, alpha-2-HS-glycoprotein preproprotein (AHSG), and sedoheptulokinase (SHPK) were down-regulated in CMECs during I/R in response to inflammation and oxygen stress. The expression of these pro-inflammatory proteins was increased in serum upon acute inflammation [19] [20] [21] [22] [23] . Feedback regulation might be involved in reducing the secretion of these proteins in CMECs. LTF is an iron-binding glycoprotein and involved in several biological functions, including iron absorption, antioxidative activities, and regulating the systemic immune response [24] . The present study showed that LTF is significantly down-regulated in CMECs during I/R, similar to a previous study [25] . According to the classical research of Ambrosio [26] , the no-reflow area has a large number of neutrophils and substantial platelet aggregation, which may be the main cause of capillary vessel embolism. The intracellular levels of A2M, serum albumin preproprotein (ALB), and APOA1 decreased, and these proteins participated in the regulation of platelet degranulation, leading to cell aggregation, which has not been previously reported.
We summarized some I/R-related proteins in previous studies and analyzed their relationships, such as P-selection (SELP), erythropoietin (EPO), hypoxia inducible factor-1 (HIF1), thromboxane synthase (TBSAX1), tryptophan hydroxylase 1 (TPH1), superoxide dismutase 1 (SOD1), matrix metalloproteinase-1 (MMP1), interleukin 8 (IL8), monocyte chemoattractant protein-1 (CCL2), and tumor necrosis factors(TNF). They were identified in several studies to take part in the regulation of multiple cellular processes. These proteins were classified according to gene ontology entries in GeneMANIA. The GeneMANIA analysis predicted a potential interaction among all these reported proteins, which were summarized (see supplementary material, Suppl. Fig. 1 ). Inflammation and oxidative stress have been widely accepted to be key pathological processes of CMECs. In our analysis, we identified a complete network of proteins associated with I/R. In the case of ischemia and hypoxia, vascular and endothelial tissues may release inflammatory factors, including HIF [18] , SOD1, NFκB [27, 28] . ECs normally regulate the release of vasoconstriction factors (ET1, TXA2) and diastolic factors (prostaglandins and adenosine oxidase) to maintain balance, which is disrupted in ischemia-reperfusion injury [29] . The adhesion molecules P-selectin and ICAM1 are involved in mediating the cell adhesion effect between neutrophils and ECs during I/R [30] . Furthermore, as a family of more than twenty secreted and cell-surface end peptidases, matrix metalloproteinases (MMPs) also participate in the process [31] . Our analysis further explored their interaction as the supplement of the previous studies. For example, NFκB could down-regulate the expression of MARK1, thus inhibiting the expression of TNF.
Conversely, it could also be up-regulated and chemically modified by MARK1. In addition, NFκB was up-regulated by IL1B, IL-8, IL18 and HIF, however, it had different effects on these proteins. It could down-regulate the expression of HIF, while it had a co-expression effect and physical interaction with IL1B, IL-8. Also, CCL2 was found to have the physical interaction and predicted TFactor regulation with NFκB. There was still some unclear interactions among different factors, such as between NFκB and SOD1.
Accumulating studies suggest that TXL mediates endothelium preservation in a mechanism that improves cardiac functions [12, 32, 33] . In the previous studies, we have found that TXL protects ECs against MIRI through the PKA/CREB/eNOS pathway [13] and protects endothelial connections through regulating the expression of VE-cadherin [34] . We demonstrated in the present study that TXL protected CMECs against I/R injury via the regulation of various proteins and the activation of different pathways regulated by these proteins. Here, we introduce some representative proteins and their functions and biological processes.
Several proteins, such as peptidyl-prolyl cis-trans isomerase (PPIL) and HEAT repeatcontaining protein 1 (HEATR1), were down-regulated by I/R but up-regulated with TXL treatment in our study. For example, the stress-responsive protein PPIL4, which is involved in protein folding, reactive oxygen species neutralization, and stress protection accumulated [35] . However, no related research regarding these proteins explored their functions in MIRI. These proteins were obviously down-regulated during I/R, whereas TXL treatment up-regulated their expression in CMECs, which may be a part of the protective mechanism of TXL. Through the GO analysis, we found that these proteins were involved in different functions and pathways.
In the present study, some proteins exhibited no significant difference in CMECs during I/R but decreased with TXL treatment. Angiopoietin-2 (ang2, ANGPT2), a negative regulator of angiogenesis [36] , is stored in ECs and released in response to homeostatic reactions including inflammation and hypoxia [37, 38] . Ang2 disrupts EC-EC junctions and induces vascular leakage in various stress conditions [39] . CTGF regulates cell adhesion, migration, and the production of extracellular matrix (ECM) proteins in various biological processes [40] . It was demonstrated that H/R increased CTGF expression in ECs and influenced fibroblast differentiation into myofibroblasts [41] . This finding is consistent with our forecast and may suggest the following mechanisms of TXL: anti-fibrosis, enhancement of angiogenesis, and vasodilatation effects. As shown in Fig. 5 and (see supplementary material) Suppl. Table  2 , CTGF was involved in the regulation of actin filament bundling, whereas ANGPT2 had an effect on the regulation of cell migration, cellular component movement, and cellular response to stimulus. As mentioned above, our study demonstrated that TXL significantly decreased the expression of ANGPT2 under H/R condition, whereas combined treatment of TXL with overexpression of ANGPT2, the anti-apoptotic, pro-proliferation, pro-migration, pro-angiogenesis effects of TXL were remarkably attenuated, indicating that ANGPT2 had a negative regulation of cell survival, cell proliferation, cell migration and angiogenesis in CMECs. Silencing ANGPT2 expression may be one of the critical protective mechanisms of TXL.
Our study showed that TXL increased the expression of various protective proteins in CMECs during I/R. Sox17 is an important factor in angiogenesis, vascular remodeling and EC differentiation, which could induce functional angiogenesis after cerebral ischemia [42] . HOMX1 is a stress response and cytoprotective protein and protects cardiomyocytes against I/R injury through generating the antioxidant bilirubin and the anti-inflammatory substance carbon monoxide (CO) in rat hearts [43] . RGCC is involved in cellular differentiation, inflammation and fibrosis and is a cell cycle activator [44] . These proteins participated in the response to oxygen levels, response to stimulus, cell migration, and cell proliferation in our study. To further validate the functions of HMOX detected by GO analysis, HMOX inhibitor TinPPIX was applied. It was observed that targeted inhibition of HMOX significantly eliminated the protective effects of TXL on H/SD-induced apoptosis, and suppressed cell migration, cell proliferation, and tube formation. In this regard, it is reasonable to conclude that HMOX was one of protective proteins mediating the beneficial effects of TXL in our study, which correlate well with the previous reports. In addition, these proteins had complicated effects with different proteins, such as APOA1, which is involved in the regulation of lipoprotein and enzyme activator activity. Other proteins, such as SQSTM1, had no related reports in previous studies. In our study, these proteins were involved in the regulation of cell autophagy and cell apoptosis and the response to stimulus during IR. Furthermore, TXL significantly decreased the levels of ANGPT2, CTGF, and CTSL. These proteins were related to oxidative stress, inflammatory, metabolic and biosynthetic processes in our analysis.
There are some limitations of our study. First, we use TMT-labeled proteomic to detect the expression of 4537 proteins which have been already known. However, some unknown proteins or proteins outside the detected proteins may be neglected. Second, our study only focus on the regulation of protein level, thus, more molecular biology experiments are needed in further study. Third, the expression of these proteins and their functions may change over time with the progress of the ischemia reperfusion injury. Hence, more time points for testing may be necessary.
In summary, TMT labeling proteomics is a method to comprehensively study I/R injury upon TXL treatment at the molecular level. We identified 50 differentially expressed proteins in CMECs that were connected to ischemia reperfusion injury and involved in numerous functions and pathways. I/R significantly altered the expression of various proteins in CMECs, whereas TXL treatment modulated factor secretion. These findings suggested that TXL may protect microvascular ECs against I/R injury through inhibition of inflammatory chemokine secretion, reductions in oxidative stress factors, and regulation of multicellular metabolic processes. Li et al.: Proteomics in CMECs after I/R and TXL Treatment Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
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